AstraZeneca Champions Maryland Manufacturing with $2 billion Investment
AstraZeneca is investing $2 billion to develop its biologics facilities in Maryland, advancing the company’s broader drive to bolster manufacturing capabilities across the US.
AstraZeneca is investing $2 billion to develop its biologics facilities in Maryland, advancing the company’s broader drive to bolster manufacturing capabilities across the US.